SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice
Open accessPublished version of a preprint
Abstract
The COVID-19 pandemic continues to spread throughout the world with an urgent need for a safe and protective vaccine to effectuate herd protection and control the spread of SARS-CoV-2. Here, we report the development of a SARS-CoV-2 subunit vaccine (NVX-CoV2373) from the full-length spike (S) protein that is stable in the prefusion conformation. NVX-CoV2373 S form 27.2-nm nanoparticles that are thermostable and bind with high affinity to the human angiotensin-converting enzyme 2 (hACE2) receptor. In mice, low-dose NVX-CoV2373 with saponin-based Matrix-M adjuvant elicit high titer anti-S IgG that blocks hACE2 receptor binding, neutralize virus, and protects against SARS-CoV-2 challenge with no evidence of vaccine-associated enhanced respiratory disease. NVX-CoV2373 also elicits multifunctional CD4 + and CD8 + T cells, CD4 + follicular helper T cells (Tfh), and antigen-specific germinal center (GC) B cells in the spleen. In baboons, low-dose levels of NVX-CoV2373 with Matrix-M was also highly immunogenic and elicited high titer anti-S antibodies and functional antibodies that block S-protein binding to hACE2 and neutralize virus infection and antigen-specific T cells. These results support the ongoing phase 1/2 clinical evaluation of the safety and immunogenicity of NVX-CoV2373 with Matrix-M (NCT04368988).
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Peptide-based antigen assembled into nanoparticles have been developed for vaccination against SARS-CoV-2.
“Peptide-based antigen assembled into nanoparticles have also been developed for vaccination against SARS-CoV-2 78 .”
From Nanotechnology approaches for global infectious diseases (2021) · cites this paper as [78]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
The citation lists haven’t been fetched yet
References 34 · Cited by 508
- Authors
- Tian, J.-H., Patel, N., Haupt, R., Zhou, H., Weston, S., Hammond, H., Logue, J., Portnoff, A. D., Norton, J., Guebre-Xabier, M., Zhou, B., Jacobson, K., Maciejewski, S., Khatoon, R., Wisniewska, M., Moffitt, W., Kluepfel-Stahl, S., Ekechukwu, B., Papin, J., Boddapati, S., Jason Wong, C., Piedra, P. A., Frieman, M. B., Massare, M. J., Fries, L., Bengtsson, K. L., Stertman, L., Ellingsworth, L., Glenn, G., & Smith, G.
- Affiliations
- Novavax (United States) (US)
- University of Maryland, Baltimore (US)
- University of Oklahoma Health Sciences Center (US)
- Catalent (United States) (US)
- Baylor College of Medicine (US)
- Novavax (Sweden) (SE)
- Corresponding author
- Smith, Gale
- ORCID
- Venue
- Nature Communications
- Published
- 2021-01-14
- Volume
- 12
- Issue
- 1
- Pages
- 372-372
- ISSN
- 2041-1723 (ISSN-L)
- PMC
- PMC7809486
- OpenAlex
- W3123053754
- Cited by
- 508
- References
- 34
- Citations by year
- 2026: 19 · 2025: 40 · 2024: 61 · 2023: 95 · 2022: 114 · 2021: 152 · 2020: 27
- FWCI
- 33.41
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Nature Communications (publishedVersion, cc-by)
- bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion)
- Research Square (acceptedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, other-oa)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Coalition for Epidemic Preparedness Innovations
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Life Sciences › Agricultural and Biological Sciences › Animal Science and Zoology › Animal Virus Infections Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › vaccines and immunoinformatics approaches
- Keywords
- NVX-CoV2373, SARS-CoV-2 spike protein, subunit vaccine, neutralizing antibodies, vaccine immunogenicity, T cell response, T follicular helper cells, germinal center B cells, vaccine safety, baboon model, mouse model
- MeSH terms
- Angiotensin-Converting Enzyme 2, COVID-19, SARS-CoV-2, COVID-19 Vaccines, Animals, Antibodies, Viral, Disease Models, Animal, Female, Male, Mice, Inbred BALB C, Papio, T-Lymphocytes, Vaccines, Subunit, Mice, Antibodies, Neutralizing, Spike Glycoprotein, Coronavirus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
